Evan is a litigation associate in Wilson Sonsini Goodrich and Rosati’s San Diego office, where he focuses his practice on patent litigation in the areas of pharmaceuticals, biologics, and medical devices. Evan is experienced in Hatch-Waxman litigation, and leverages his technical background in pharmacology to effectively represent pharmaceutical companies in complex ANDA cases.
Evan has experience managing every stage of district court litigation, including pre-suit diligence, discovery, claim construction, invalidity and infringement contentions, expert discovery, and trial preparation.
While pursuing his Ph.D., Evan focused his research on preparing and testing various pharmaceutical compositions for the treatment of gastrointestinal cancers. His technical experience includes pharmacology, cellular and molecular biology, chemistry, and drug design.
As COVID-19 continues to rapidly sweep the globe, government agencies at all levels are taking measures to curb the spread of the virus. Private companies have announced plans for and advancements in testing, antivirals and vaccines, leading some members of Congress to raise concerns about whether these medical countermeasures “will be affordable and accessible to the public” in light of companies’ ability to enforce their patent rights and exclude competitors. See Kevin J. Hickey, Cong. Research Serv., LSB10422, COVID-19 Medical Countermeasures: Intellectual Property and Affordability (March 18, 2020). This, in turn, has led to concerns that the government may appropriate private intellectual property rights in order to combat the virus.